source
- AstraZeneca and Amgen report positive Phase 3 results for Tezspire in eosinophilic esophagitisAstraZeneca and Amgen announced that their joint drug Tezspire met primary and secondary endpoints in a late-stage Phase 3 trial for eosinophilic esophagitis. The antibody targets TSLP and had pre…
- Medtronic and Given Imaging issue early alert for Bravo CF esophageal pH capsule delivery devices due to attachment failuresThe FDA's Center for Devices and Radiological Health issued an Early Alert about a potential high‑risk issue with Medtronic’s Bravo CF esophageal pH monitoring capsule delivery devices. The proble…fda medwatch · 19h agoRegulatoryNegative